Axsome Therapeutics announced that it has reached a settlement agreement with Hikma Pharmaceuticals USA, resolving patent litigation related to Axsome’s drug Sunosi (solriamfetol). The litigation arose from Hikma’s submission of an Abbreviated New Drug Application to the FDA seeking approval to market a generic version of Sunosi. Under the settlement, Axsome will grant Hikma a license to sell its generic version starting on or after March 1, 2040, or September 1, 2040, if pediatric exclusivity is granted. The agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. Litigation against other parties regarding Sunosi remains ongoing.